CN1404471A - 取代的哌嗪化合物 - Google Patents
取代的哌嗪化合物 Download PDFInfo
- Publication number
- CN1404471A CN1404471A CN01805442A CN01805442A CN1404471A CN 1404471 A CN1404471 A CN 1404471A CN 01805442 A CN01805442 A CN 01805442A CN 01805442 A CN01805442 A CN 01805442A CN 1404471 A CN1404471 A CN 1404471A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- hydrogen
- halogen
- aryl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/54—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/58—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18430600P | 2000-02-22 | 2000-02-22 | |
| US18418200P | 2000-02-22 | 2000-02-22 | |
| US18445700P | 2000-02-22 | 2000-02-22 | |
| US60/184,306 | 2000-02-22 | ||
| US60/184,457 | 2000-02-22 | ||
| US60/184,182 | 2000-02-22 | ||
| US20639600P | 2000-05-23 | 2000-05-23 | |
| US60/206,396 | 2000-05-23 | ||
| US20926200P | 2000-06-05 | 2000-06-05 | |
| US60/209,262 | 2000-06-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1404471A true CN1404471A (zh) | 2003-03-19 |
Family
ID=27539118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN01805442A Pending CN1404471A (zh) | 2000-02-22 | 2001-02-22 | 取代的哌嗪化合物 |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1259493A2 (cg-RX-API-DMAC7.html) |
| JP (2) | JP3980885B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR100595942B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN1404471A (cg-RX-API-DMAC7.html) |
| AR (1) | AR029229A1 (cg-RX-API-DMAC7.html) |
| AU (2) | AU3862301A (cg-RX-API-DMAC7.html) |
| BR (1) | BR0108592A (cg-RX-API-DMAC7.html) |
| CA (2) | CA2657986A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL151178A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA02008213A (cg-RX-API-DMAC7.html) |
| NO (1) | NO324837B1 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ520782A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI236471B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2001062744A2 (cg-RX-API-DMAC7.html) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102875490A (zh) * | 2012-10-19 | 2013-01-16 | 四川大学 | 一种用于制备雷诺嗪的合成方法 |
| CN107043361A (zh) * | 2017-05-25 | 2017-08-15 | 合肥医工医药有限公司 | 治疗心绞痛的化合物、制备方法及用途 |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ520780A (en) * | 2000-02-18 | 2006-04-28 | Cv Therapeutics Inc | Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure |
| MXPA04000565A (es) * | 2001-07-19 | 2005-06-17 | Cv Therapeutics Inc | Compuestos de piperazina sustituidos y su uso como inhibidores de oxidacion de acidos grasos. |
| US7001909B2 (en) | 2001-07-19 | 2006-02-21 | Cv Therapeutics, Inc. | Substituted heterocyclic compounds |
| EP1806346B1 (en) * | 2002-12-05 | 2009-07-22 | Cv Therapeutics, Inc. | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors |
| ATE365737T1 (de) | 2002-12-05 | 2007-07-15 | Cv Therapeutics Inc | Substituierte piperazinverbindungen undderen verwendung als fettsuureoxidationsinhibitoren |
| NZ541069A (en) | 2003-01-03 | 2008-09-26 | Cv Therapeutics Inc | Piperazine derivatives as fatty acid oxidation inhibitors |
| CA2530376A1 (en) * | 2003-06-23 | 2005-01-06 | Cv Therapeutics, Inc. | Urea derivatives of piperazines and piperidines as fatty acid oxidation inhibitors |
| CA2550257A1 (en) | 2003-12-18 | 2005-07-07 | Cv Therapeutics, Inc. | 1-akan-2-ol substituted piperazine and piperidine compounds |
| US7271169B2 (en) * | 2004-09-08 | 2007-09-18 | Cv Therapeutics, Inc. | Substituted heterocyclic compounds |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS584774A (ja) * | 1981-06-23 | 1983-01-11 | ジヤンセン・フア−マシユ−チカ・ナ−ムロ−ゼ・フエンノ−トシヤツプ | N−アリ−ル−ピペラジンアルカンアミド類 |
| US4766125A (en) * | 1981-06-23 | 1988-08-23 | Janssen Pharmaceutica N.V. | N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia |
| US4567264A (en) * | 1983-05-18 | 1986-01-28 | Syntex (U.S.A.) Inc. | Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry |
| US4558129A (en) * | 1983-05-18 | 1985-12-10 | Syntex (U.S.A.) Inc. | Benzodioxanyl-hydroxyethylene-piperazinyl acetanilides which effect calcium entry and β-blockade |
| FR2552083B1 (fr) * | 1983-09-15 | 1986-05-09 | Cerm Cent Europ Rech Mauvernay | Derives de (alkynyloxy-3 hydroxy-2-propyl)-4 piperazinyl-1 n-phenyl acetamide, leur preparation et leur application en therapeutique |
| ES2177601T3 (es) * | 1989-06-23 | 2002-12-16 | Syntex Llc | Ranolazina y pepeerazinas relacionadas para uso en el tratamiento de estados de choque. . |
| JPH03141258A (ja) * | 1989-10-25 | 1991-06-17 | Kowa Co | 新規なピペラジン誘導体 |
| HU209723B (en) * | 1990-10-31 | 1994-10-28 | Richter Gedeon Vegyeszet | Process for producing of piperazine derivatives |
-
2001
- 2001-02-22 NZ NZ520782A patent/NZ520782A/en unknown
- 2001-02-22 EP EP01911085A patent/EP1259493A2/en not_active Withdrawn
- 2001-02-22 CN CN01805442A patent/CN1404471A/zh active Pending
- 2001-02-22 AU AU3862301A patent/AU3862301A/xx active Pending
- 2001-02-22 IL IL15117801A patent/IL151178A0/xx unknown
- 2001-02-22 BR BR0108592-1A patent/BR0108592A/pt not_active Application Discontinuation
- 2001-02-22 WO PCT/US2001/005606 patent/WO2001062744A2/en not_active Ceased
- 2001-02-22 AR ARP010100804A patent/AR029229A1/es unknown
- 2001-02-22 AU AU2001238623A patent/AU2001238623B2/en not_active Ceased
- 2001-02-22 KR KR1020027011014A patent/KR100595942B1/ko not_active Expired - Fee Related
- 2001-02-22 MX MXPA02008213A patent/MXPA02008213A/es active IP Right Grant
- 2001-02-22 CA CA002657986A patent/CA2657986A1/en not_active Abandoned
- 2001-02-22 JP JP2001562526A patent/JP3980885B2/ja not_active Expired - Lifetime
- 2001-02-22 CA CA002400176A patent/CA2400176C/en not_active Expired - Fee Related
- 2001-04-13 TW TW090104080A patent/TWI236471B/zh not_active IP Right Cessation
-
2002
- 2002-08-20 NO NO20023954A patent/NO324837B1/no not_active IP Right Cessation
-
2007
- 2007-01-15 JP JP2007005347A patent/JP2007211009A/ja active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102875490A (zh) * | 2012-10-19 | 2013-01-16 | 四川大学 | 一种用于制备雷诺嗪的合成方法 |
| CN107043361A (zh) * | 2017-05-25 | 2017-08-15 | 合肥医工医药有限公司 | 治疗心绞痛的化合物、制备方法及用途 |
| CN107043361B (zh) * | 2017-05-25 | 2019-07-02 | 合肥医工医药股份有限公司 | 治疗心绞痛的化合物、制备方法及用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| NO20023954D0 (no) | 2002-08-20 |
| NZ520782A (en) | 2004-03-26 |
| CA2657986A1 (en) | 2001-08-30 |
| MXPA02008213A (es) | 2004-04-05 |
| KR20020079893A (ko) | 2002-10-19 |
| WO2001062744A3 (en) | 2002-02-07 |
| IL151178A0 (en) | 2003-04-10 |
| NO324837B1 (no) | 2007-12-17 |
| CA2400176C (en) | 2009-04-28 |
| JP2003531116A (ja) | 2003-10-21 |
| AU2001238623B2 (en) | 2004-09-23 |
| EP1259493A2 (en) | 2002-11-27 |
| KR100595942B1 (ko) | 2006-07-03 |
| NO20023954L (no) | 2002-09-30 |
| AR029229A1 (es) | 2003-06-18 |
| BR0108592A (pt) | 2004-06-29 |
| JP3980885B2 (ja) | 2007-09-26 |
| JP2007211009A (ja) | 2007-08-23 |
| CA2400176A1 (en) | 2001-08-30 |
| TWI236471B (en) | 2005-07-21 |
| WO2001062744A2 (en) | 2001-08-30 |
| AU3862301A (en) | 2001-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1303074C (zh) | 作为脂肪酸氧化抑制剂的杂芳基烷基哌嗪衍生物 | |
| CN1037348C (zh) | 取代的5-(2-((2-芳基-2-羟乙基)氨基)丙基)-1,3-苯并间二氧杂环戊烯的制备方法 | |
| CN1134414C (zh) | 用作神经激肽拮抗药的取代肟、腙和链烯烃 | |
| CN1066436C (zh) | 新的环己烷和环己烯类衍生物 | |
| CN1084743C (zh) | 毒蕈碱拮抗剂 | |
| US6552023B2 (en) | Aralkyl substituted piperazine compounds | |
| CN1260222C (zh) | Mcp-1功能的拮抗物及其应用方法 | |
| CN1163484C (zh) | 4-芳酰基-哌啶-ccr-3受体拮抗剂ⅲ | |
| CN1172919C (zh) | 芳烷醇哌嗪衍生物及其在制备抗抑郁症药物中的应用 | |
| US6451798B2 (en) | Substituted alkyl piperazine derivatives | |
| JP2007211009A (ja) | 置換ピペラジン化合物 | |
| CN1270585A (zh) | 取代的1,2,3,4-四氢化萘衍生物 | |
| CN87100040A (zh) | 二芳基烷基取代的烷基胺、其制备工艺方法、应用以及含有该类化合物的药物 | |
| CN1175253A (zh) | 作为多药抗性调节剂的哌嗪-2,5-二酮衍生物 | |
| CN1529699A (zh) | 新的磺酸衍生物 | |
| CN1157376C (zh) | 芳基哌啶子基丙醇和芳基哌嗪子基丙醇衍生物和含有它们的药物 | |
| CN1756740A (zh) | 具有2,6-二取代苯乙烯基的含氮杂环衍生物 | |
| CN1111528C (zh) | 用作神经激肽拮抗药的哌嗪衍生物 | |
| CN1048214A (zh) | 新的抗心律失常药ii的制备方法 | |
| CN1234026A (zh) | 用作神经激肽拮抗剂的哌嗪并衍生物 | |
| CN1599611A (zh) | 作为哮喘治疗中的ccr-3受体拮抗剂的哌嗪衍生物 | |
| AU2001238623A1 (en) | Substituted piperazine compounds | |
| CN1296356C (zh) | Ccr-3受体拮抗剂vii | |
| CN1267412C (zh) | Ccr-3受体拮抗剂v | |
| CN1144805C (zh) | 桥接双哌啶化合物,其制备方法和中间体及用于治疗心律失常的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20030319 |